Pardo Geoffrey B 4

What Happened
Geoffrey B. Pardo, a director of SpyGlass Pharma, received a grant of 27,400 derivative shares on Feb 5, 2026. The award shows a $0.00 acquisition price (i.e., no cash paid). This is a compensation award (not an open-market purchase or sale).

Key Details

• Transaction date: February 5, 2026; Form 4 filed February 9, 2026 (timely filing).
• Shares granted: 27,400 derivative shares; reported acquisition price: $0.00.
• Shares owned after transaction: Not disclosed in this filing.
• Vesting footnote: Award vests monthly over 36 months — 1/36th each month starting on the grant date (Feb 5, 2026) — contingent on Pardo continuing as an Outside Director under the issuer’s 2026 Equity Incentive Plan (Footnote F1).
• Transaction type code: A = Award/Grant (derivative securities).

Context This grant appears to be board compensation that vests over three years rather than an immediate market purchase or sale. Because the award vests monthly, the director will not have full ownership until vesting occurs and any further filings (e.g., sales or exercises) would show if/when shares become tradable.